Please assess the completion status of the following clinical trial:

Trial Title: Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cesarean delivery~* Meet facility guidelines for postpartum venous thromboembolism (VTE) prophylaxis: Presence of 1 major, or 2 or more moderate, risk factors.~* Major risk factors: history of venous thromboembolism, high risk thrombophilia, BMI ≥40, high risk medical comorbidities (heart disease, sickle cell disease, systemic lupus erythematosus, inflammatory bowel disease), cesarean hysterectomy, nephrotic range proteinuria, or cesarean intrapartum/during labor~* Moderate risk factors: BMI \> 30, multifetal pregnancy, postpartum hemorrhage (\>1L blood loss), tobacco use, non-laboring or elective cesarean, preeclampsia, infection, preterm delivery (\< 37 weeks gestational age), age \> 35 years, low risk thrombophilia, family history of venous thromboembolism, stillbirth, varicose veins, prolonged labor (\> 24 hours)~Exclusion Criteria:~* Contraindication to anticoagulation~* Plan for therapeutic anticoagulation (antepartum or postpartum)~* Known renal dysfunction (Creatinine clearance \< 30 mL/minute)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Weight-based LMWH (Type: EXPERIMENTAL): Participants will receive a weight-based dose of prophylactic enoxaparin.~- For all BMI groups: 0.5mg/kg rounded to the nearest 10mg will be injected subcutaneously every 12 hours
- Fixed LMWH (Type: ACTIVE_COMPARATOR): Participants will receive a fixed dose of prophylactic enoxaparin.~* For BMI \<40: 40mg injected subcutaneously every 24 hours~* For BMI \> or = to 40: 40mg injected subcutaneously every 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).